WALTHAM, Mass.--(BUSINESS WIRE)--EUROIMMUN, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its EUROIMMUN® Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) (research use only) was cited by the ...
A new study maps how the immune system clears dengue without symptoms, revealing protective responses that could guide safer, ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Dengue Vaccines: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug ...
"Dengue Fever Clinical Trials"DelveInsight's,“Dengue Fever - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape ...
The majority of dengue virus infections are mild; only a small proportion of patients develop overt complications, which can include systemic vascular leak syndrome, bleeding, and organ impairment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results